

EUROPEAN CANCER RESEARCH *Summit* *May 3, 2021* | PORTO, PORTUGAL

PRELIMINARY PROGRAM (CET)

Please note that in this version of the program, the time is set as CET (Central European Time).

09:30-10:00 - REGISTRATION

10:00-10:30 - WELCOME AND OPENING SESSION / REMARKS

Rui Henrique, *Chairman of the Board, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal*

Julio E. Celis, *Chair of the Science Policy Committee of the European Academy of Cancer Sciences (EACS) and Danish Cancer Society Research Centre, Denmark*

Marta Temido, *Minister for Health, Portugal*

Stella Kyriakides, *European Commissioner for Health and Food Safety, European Union*

Manuel Heitor, *Minister for Science, Technology and Higher Education, Portugal*

Mariya Gabriel, *European Commissioner for Innovation, Research, Culture, Education & Youth, European Union*

10:30-12:30 - SESSION 1. INFRASTRUCTURE FOR TRANSLATIONAL RESEARCH

Chair: Ulrik Ringborg, *Cancer Center Karolinska, Stockholm, Sweden*

Presentations:

> **Basic/preclinical research: Generating proof of concept clinical trials is the engine for translational cancer research** | **Alexander Eggermont**, *Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands*

> **The Comprehensive Cancer Centre: An essential infrastructure component** | **Simon Oberst**, *Cancer Research UK, Cambridge Center, Cambridge, UK*

> **Molecular and digital pathology is essential to develop personalized/precision cancer medicine** | **Fátima Carneiro**, *University of Porto, Porto, Portugal*

> **Immunotherapy: An expanding treatment modality** | **Laurence Zitvogel**, *Gustave Roussy Cancer Campus, Grand Paris, France*

> **Liquid biopsies: Expanding diagnostic procedures for both therapeutics and prevention** | **Olli Kallioniemi**, *Science for Life Laboratory, Stockholm, Sweden*

> **Acquisition of clinical and biological data: Implementation of computational sciences (Artificial Intelligence)** | **Jan Korbel**, *European Molecular Biology Laboratory, Heidelberg, Germany*

> **EC Knowledge Centre on Cancer** | **Guy Van den Eede**, *European Commission, Brussels, Belgium*

Debate (to be confirmed):

> **Douglas Hanahan**, *École polytechnique fédérale de Lausanne - EPFL, Lausanne, Switzerland*

> **Stefan Fröhling**, *National Center for Tumour Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany*

> **Péter Nagy**, *National Institute of Oncology, Budapest, Hungary*

> **Ken Mastris**, *President of European Cancer Patient Coalition (ECPC), Brussels, Belgium*

> **Alexander Roediger**, *The European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium*

> **Raquel Seruca**, *Institute for Investigation and Innovation in Health (i3S), Porto, Portugal*

12:30-12:50 - COFFEE BREAK

12:50-14:40 - SESSION 2. INFRASTRUCTURE FOR CLINICAL AND PREVENTION TRIALS

Chair: Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain

Presentations:

- > Quality assurance of clinical trials structures: harmonisation of technical requirements to support multinational institutional collaborations in next-generation clinical trials | **Denis Lacombe**, European Organisation for Research and Treatment of Cancer, Brussels, Belgium
- > Molecular pathology for patient stratification in multicentre clinical trials | **Paolo Nuciforo**, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain
- > Genomics: From discovery to bench-side genomics | **Emile Voest**, The Netherlands Cancer Institute, Amsterdam, The Netherlands
- > Modern Imaging in Oncology | **Regina Beets-Tan**, The Netherlands Cancer Institute, Amsterdam, The Netherlands
- > Repeated biopsies (fine needle aspiration and liquid biopsies), biobanking and clinical trials registries with clinical and biological information | **Benjamin Besse**, Institute Gustave-Roussy, Grand Paris, France
- > Development of innovative radiotherapy trials | **Vincenzo Valentini**, Policlinico Gemelli, Rome, Italy
- > Coordination of clinical trials activities from proof-of-concept trials to practice-changing clinical trials: added value compared to present treatments | **Elena Garralda**, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain
- > New concepts and opportunities in cancer prevention clinical trials | **Elisabete Weiderpass**, International Agency for Research on Cancer, Lyon, France
- > The Molecular Tumour Board: a critical infrastructure for delivery of Precision Medicine | **Júlio Oliveira**, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal

Debate (to be confirmed):

- > **Bettina Ryll**, Cancer Mission Board member, Uppsala, Sweden
- > **Susan Galbraith**, AstraZeneca, Cambridge, UK
- > **Fátima Cardoso**, Champalimaud Clinical Center, Lisbon, Portugal
- > **José Carlos Machado**, Institute for Investigation and Innovation in Health (i3S), Porto, Portugal

14:40-15:20 - LUNCH

15:20-17:10 - SESSION 3. INFRASTRUCTURE FOR OUTCOMES RESEARCH

Chair: Joachim Schüz, International Agency for Research on Cancer, Lyon, France

Presentations:

- > Outcomes research Infrastructure to support the development of primary prevention | **Joachim Schüz**, International Agency for Research on Cancer, Lyon, France
- > Outcomes research infrastructure to support the development of cancer screening | **Partha Basu**, International Agency for Research on Cancer, Lyon, France
- > Outcomes research infrastructure to support the assessment of clinical effectiveness of therapeutic innovations | **Nils Wilking**, Karolinska Institutet, Stockholm, Sweden
- > Infrastructure support for cancer specific Health-Related Quality of Life research | **Karen Steindorf**, National Center for Tumour Diseases and German Cancer Research Center, Heidelberg, Germany

- > **Outcomes research infrastructure for survivorship research** | **Françoise Meunier**, Former head of the European Organisation for Research and Treatment of Cancer, Brussels, Belgium
- > **Health economics as an integrated part of the cancer research continuum for prevention and therapeutics** | **Bengt Jönsson**, Stockholm School of Economics, Stockholm, Sweden
- > **A case study: outcomes implementation and measurement in lung cancer** | **Marta Soares**, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal

Debate (to be confirmed):

- > **Jose M. Martin-Moreno**, University of Valencia, Spain
- > **Florian Alexandru Nicula**, Institute of Oncology, Cluj-Napoca, Romania
- > **Maja Primic-Zakelj**, Institute of Oncology, Ljubljana, Slovenia & Formerly Head of Epidemiology and Cancer Registry, Ljubljana, Slovenia

17:10-17:45 - SESSION 4. EU-USA CANCER RESEARCH COOPERATION

Chair: Michael Baumann, German Cancer Research Centre (DKFZ), Heidelberg, Germany

- > **Strategic development of precision cancer medicine in the US** | **Richard Schilsky**, Past President and former Chief Medical Officer, American Society of Clinical Oncology, Alexandria, VA, USA

17:45-18:05 - PRESENTATION OF "PORTO DECLARATION ON CANCER RESEARCH" AND KEY NOTE SPEECHES:

Anton Berns, President of the EACS: Infrastructures to sustain the EU cancer mission, Brussels, Belgium

Walter Ricciardi, President, EU Cancer Mission Board, Brussels, Belgium

18:05-18:15 - CLOSING REMARKS

- > **António Sousa Pereira**, Rector, University of Porto, Porto, Portugal
- > **Rui Henrique**, Chairman of the Board, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal
- > **Julio E. Celis**, Chair of the Science Policy Committee of the European Academy of Cancer Sciences (EACS) and Danish Cancer Society Research Centre, Denmark
- > **Mariya Gabriel**, European Commissioner for Innovation, Research, Culture, Education & Youth, European Union
- > **Manuel Heitor**, Minister for Science, Technology and Higher Education, Portugal

**2021
PORTUGAL.EU**



**REPÚBLICA
PORTUGUESA**